HK1211475A1 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
HK1211475A1
HK1211475A1 HK15112282.5A HK15112282A HK1211475A1 HK 1211475 A1 HK1211475 A1 HK 1211475A1 HK 15112282 A HK15112282 A HK 15112282A HK 1211475 A1 HK1211475 A1 HK 1211475A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
HK15112282.5A
Other languages
English (en)
Chinese (zh)
Inventor
Shivang Doshi
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1211475A1 publication Critical patent/HK1211475A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112282.5A 2012-11-28 2015-12-14 Combination therapy HK1211475A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730661P 2012-11-28 2012-11-28
PCT/US2013/071659 WO2014085318A1 (en) 2012-11-28 2013-11-25 Combination therapy

Publications (1)

Publication Number Publication Date
HK1211475A1 true HK1211475A1 (en) 2016-05-27

Family

ID=49753505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112282.5A HK1211475A1 (en) 2012-11-28 2015-12-14 Combination therapy

Country Status (12)

Country Link
US (1) US9408847B2 (bg)
EP (1) EP2925365A1 (bg)
JP (2) JP2016501221A (bg)
KR (1) KR20150089053A (bg)
CN (1) CN104812414A (bg)
AU (4) AU2013352406A1 (bg)
BR (1) BR112015012197A8 (bg)
CA (1) CA2891938A1 (bg)
HK (1) HK1211475A1 (bg)
MX (1) MX2015006809A (bg)
RU (1) RU2015125307A (bg)
WO (1) WO2014085318A1 (bg)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012279117A1 (en) * 2011-07-01 2014-01-09 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
AR103894A1 (es) 2015-03-10 2017-06-14 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del estimulador del gen interferón
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3156406A1 (en) * 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
HRP20220619T1 (hr) * 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
JP7219224B2 (ja) * 2017-03-16 2023-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳癌の治療のための組合せ療法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
SG11201912473PA (en) 2017-06-22 2020-01-30 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI750539B (zh) * 2018-11-23 2021-12-21 大陸商蘇州亞盛藥業有限公司 新穎藥物組成物及其用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800327A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer

Also Published As

Publication number Publication date
EP2925365A1 (en) 2015-10-07
JP2019031500A (ja) 2019-02-28
BR112015012197A8 (pt) 2019-10-01
CN104812414A (zh) 2015-07-29
AU2019200881A1 (en) 2019-02-28
AU2013352406A1 (en) 2015-06-04
RU2015125307A (ru) 2017-01-10
WO2014085318A1 (en) 2014-06-05
AU2016262781A1 (en) 2016-12-15
US20150306104A1 (en) 2015-10-29
CA2891938A1 (en) 2014-06-05
MX2015006809A (es) 2015-08-06
AU2018200323A1 (en) 2018-02-01
KR20150089053A (ko) 2015-08-04
JP2016501221A (ja) 2016-01-18
BR112015012197A2 (pt) 2017-07-11
US9408847B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
HK1211475A1 (en) Combination therapy
HK1203963A1 (en) Novel therapeutic agents
ZA201305897B (en) Combination therapy
GB201212513D0 (en) Therapeutic agents
EP2934531A4 (en) COMBINATION
PL2854944T3 (pl) Urządzenia do fototerapii
ZA201400120B (en) Combination therapy
GB201217439D0 (en) Combination therapy
EP2911673A4 (en) COMBINATION
GB201217704D0 (en) Therapeutic agents
EP2701744A4 (en) COMBINATION THERAPY
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
IL238174A0 (en) Combined treatment with Valasertiv
EP2804853A4 (en) THERAPEUTIC USES
EP2925728A4 (en) COMBINATION
GB201211543D0 (en) Combination therapy
IL236873A0 (en) therapeutic compounds
ZA201405764B (en) Novel therapeutic agents
GB201223021D0 (en) Therapeutic agents
EP2908816A4 (en) ASSOCIATION
EP2908815A4 (en) COMBINATION
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201211135D0 (en) Treatment